We practice what we implement, with full deployment handled by our in-house team. Our architecture is built on MAS (multi-agent systems) and is deployable across AWS, GCP, or hybrid environments. We provide on-demand AI engineers and architects, and our internal agents power our own research, sales, and QA. All of this is backed by a network of certified partners.
An AI-powered tool that helps oncologists generate accurate,
evidence-based breast cancer treatment protocols.
Uses patient specific data
Generates treatment protocols aligned with guidelines
Phase 2 & 3 clinical trials
Supports all stages of care: from diagnosis to post-treatment review
Integrates into tumour board workflows
Breast cancer is the #1 cancer in the UAE
. 1,456 new cases in 2023
Manual planning causes delays & variability
. A 4-week delay increases mortality by 10%
Many hospitals lack consistent access to expertise
. Over 77% of cancer patients are Non-Emirati, often treated in under-resourced centres
Reduces doctor workload and human error
Enables junior doctors to follow gold-standard protocols
Helps tumour boards reach consensus faster
Improves treatment equity across public and private hospitals
Aligns with MOHAP & DHA digital health priorities
Avoidable loss of life.
Faster Treatment = Higher Survival Rates
. Reduces long-term care costs
Personalised, Evidence-Based Care
. Decreases unnecessary treatments & hospital readmissions
Improved Access Across Facilities
. Cuts travel & private consultation costs
Up to 70% Reduction in Planning Time
. Saves clinician hours
Junior Doctors Perform at Senior Level
. Reduces dependency on costly senior staffing
Traceable, Explainable AI Support
. Lowers medico-legal risk & associated insurance premiums
H2x Patient Throughput per Day
. Higher revenue per doctor without increasing headcount
Cost-Effective Pathway Suggestions
. Charity hospitals: AI recommends lowest-cost compliant treatments
. Private hospitals: Saves on unnecessary tests, reduces malpractice risks
Reduced Protocol Errors & Litigation Exposure
. Avoids legal costs tied to misdiagnosis or incorrect treatments
Audit-Ready Workflows
. Saves on administrative overhead for compliance
National Alignment Reduces Survival Disparities (2.9%)
. Avoids social & economic costs from regional inequity
Supports MOHAP/DHA Digital Health Strategy
. Enables scalable public-private AI adoption
Helps Reduce the £3.6B/year Economic Burden of Breast Cancer
. Through early detection, standardised treatment, and outcome-driven care
Sales teams constantly face the challenge of identifying the right leads, nurturing prospects, and closing deals efficiently. For our partners at FuseBase, we’ve developed an Automated Agentic AI Lead Generation application that operates 24/7 through a coordinated team of specialised AI agents. These agents autonomously scan and qualify high-potential leads, engage prospects with personalised outreach, score and prioritise based on intent, and automate follow-ups—allowing sales teams to focus on closing. At SensAI, we harness the power of Multi-Agent Systems (MAS), where intelligent AI agents work collaboratively to optimise workflows, adapt in real time, and boost productivity. This approach not only accelerates decision-making but also scales seamlessly across enterprise operations, enhancing human-AI collaboration for superior outcomes.